An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care

Official record

Identifier

NCT07843758

Recruiting locations

country

Switzerland

Interventions studied

Not provided in the official record

Lead sponsor

Novartis Pharmaceuticals

Target enrolment

1525 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Completed

First posted

Sep 28, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years – 100 Years

Sex

MALE

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion criteria:

1. Had an International Classification of Diseases, 9th or 10th Revision, Clinical Modification (ICD-9-CM or ICD-10-CM) diagnosis of prostate cancer (PC) (ICD-9-CM 185x or ICD-10-CM C61x).
2. Had at least two documented clinical visits, on different days, occurring on or after 01 Jan 2013.
3. Included in probabilistic sample of patients queued for review via abstraction.
4. Had diagnosis of metastatic disease on or after 01 Jan 2013.
5. Histology was confirmed as adenocarcinoma of the prostate.
6. Had confirmed mCRPC diagnosis.
7. Treated with an ARPI-containing line of therapy (LOT; i.e., index therapy) in the mCRPC setting immediately after progression on one previous ARPI-containing line (in any setting, Hormone Sensitive PC or castration-resistant PC), as defined per the health research database's LOT rules and confirmed via abstraction.
8. 18 years of age or older at the start of index therapy.
9. Had an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0-1 within 30 days before or up to 7 days after index date, or unknown ECOG PS.

Exclusion criteria:

1. Female sex.
2. Had evidence of untreated brain metastases.
3. Had history of cardiac comorbidities, infection with hepatitis B or C, or spinal cord compression that would indicate significant risk to PSMAfore trial participation.
4. Diagnosis of an active additional malignancy (i.e., other than prostate cancer).
5. Evidence of biomarker status that would indicate eligibility for treatment other than ARPI, or better prognosis.
6. Evidence of prior treatment with therapies that potentially affect study outcomes (e.g., radiopharmaceuticals, taxane, immunotherapy or biological therapy, clinical study drug (CSD), or 177Lu-PSMA-617).
7. Had evidence of inadequate organ function.
8. Had evidence of low levels of albumin (\< 2.5 g/dL).
9. Had evidence of a negative PSMA-PET scan.

Other protocol-defined inclusion/exclusion criteria may apply.

Indexed under

Prostate Cancer